vs
Side-by-side financial comparison of JOINT Corp (JYNT) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
JOINT Corp is the larger business by last-quarter revenue ($15.2M vs $9.3M, roughly 1.6× STRATA Skin Sciences, Inc.). JOINT Corp runs the higher net margin — 6.5% vs 0.6%, a 5.9% gap on every dollar of revenue. On growth, JOINT Corp posted the faster year-over-year revenue change (3.1% vs -3.0%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -28.6%).
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
JYNT vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.2M | $9.3M |
| Net Profit | $991.1K | $58.0K |
| Gross Margin | 81.4% | 61.8% |
| Operating Margin | 4.9% | 5.3% |
| Net Margin | 6.5% | 0.6% |
| Revenue YoY | 3.1% | -3.0% |
| Net Profit YoY | 5510.5% | 101.3% |
| EPS (diluted) | $0.06 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.2M | $9.3M | ||
| Q3 25 | $13.4M | $6.9M | ||
| Q2 25 | $13.3M | $7.7M | ||
| Q1 25 | $13.1M | $6.8M | ||
| Q4 24 | $14.7M | $9.6M | ||
| Q3 24 | $30.2M | $8.8M | ||
| Q2 24 | $30.3M | $8.4M | ||
| Q1 24 | $29.7M | $6.8M |
| Q4 25 | $991.1K | $58.0K | ||
| Q3 25 | $855.0K | $-1.6M | ||
| Q2 25 | $93.4K | $-2.6M | ||
| Q1 25 | $967.8K | $-2.1M | ||
| Q4 24 | $17.7K | $-4.6M | ||
| Q3 24 | $-3.2M | $-2.1M | ||
| Q2 24 | $-3.6M | $-91.0K | ||
| Q1 24 | $947.0K | $-3.4M |
| Q4 25 | 81.4% | 61.8% | ||
| Q3 25 | 80.1% | 60.4% | ||
| Q2 25 | 79.1% | 56.2% | ||
| Q1 25 | 77.3% | 53.5% | ||
| Q4 24 | 78.4% | 61.4% | ||
| Q3 24 | 90.7% | 60.1% | ||
| Q2 24 | 90.7% | 59.0% | ||
| Q1 24 | 90.9% | 45.6% |
| Q4 25 | 4.9% | 5.3% | ||
| Q3 25 | 1.2% | -16.9% | ||
| Q2 25 | -8.6% | -30.1% | ||
| Q1 25 | -5.2% | -25.0% | ||
| Q4 24 | 5.5% | -44.7% | ||
| Q3 24 | -1.6% | -18.2% | ||
| Q2 24 | -5.9% | -5.7% | ||
| Q1 24 | -1.4% | -42.7% |
| Q4 25 | 6.5% | 0.6% | ||
| Q3 25 | 6.4% | -23.4% | ||
| Q2 25 | 0.7% | -33.6% | ||
| Q1 25 | 7.4% | -31.2% | ||
| Q4 24 | 0.1% | -47.6% | ||
| Q3 24 | -10.5% | -23.6% | ||
| Q2 24 | -11.9% | -1.1% | ||
| Q1 24 | 3.2% | -49.8% |
| Q4 25 | $0.06 | $0.14 | ||
| Q3 25 | $0.06 | $-0.36 | ||
| Q2 25 | $0.01 | $-0.62 | ||
| Q1 25 | $0.06 | $-0.51 | ||
| Q4 24 | $0.01 | $-2.01 | ||
| Q3 24 | $-0.21 | $-0.51 | ||
| Q2 24 | $-0.24 | $-0.03 | ||
| Q1 24 | $0.06 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $15.1M | $2.9M |
| Total Assets | $61.0M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | $7.9M | ||
| Q3 25 | $29.7M | $7.1M | ||
| Q2 25 | $29.8M | $6.0M | ||
| Q1 25 | $21.9M | $6.5M | ||
| Q4 24 | $25.1M | $7.3M | ||
| Q3 24 | $20.7M | $7.1M | ||
| Q2 24 | $17.5M | $5.5M | ||
| Q1 24 | $18.7M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $15.1M | $2.9M | ||
| Q3 25 | $22.7M | $1.3M | ||
| Q2 25 | $23.2M | $532.0K | ||
| Q1 25 | $22.8M | $3.0M | ||
| Q4 24 | $20.7M | $5.0M | ||
| Q3 24 | $20.5M | $9.4M | ||
| Q2 24 | $23.2M | $9.5M | ||
| Q1 24 | $26.2M | $9.4M |
| Q4 25 | $61.0M | $30.5M | ||
| Q3 25 | $69.4M | $30.7M | ||
| Q2 25 | $73.2M | $29.5M | ||
| Q1 25 | $80.1M | $33.0M | ||
| Q4 24 | $83.2M | $34.9M | ||
| Q3 24 | $79.6M | $39.4M | ||
| Q2 24 | $82.4M | $38.8M | ||
| Q1 24 | $85.7M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-239.0K |
| Free Cash FlowOCF − Capex | $334.7K | $-551.0K |
| FCF MarginFCF / Revenue | 2.2% | -5.9% |
| Capex IntensityCapex / Revenue | 9.9% | 3.4% |
| Cash ConversionOCF / Net Profit | 1.86× | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-239.0K | ||
| Q3 25 | $1.8M | $-64.0K | ||
| Q2 25 | $868.6K | $-1.9M | ||
| Q1 25 | $-3.7M | $-550.0K | ||
| Q4 24 | $9.4M | $703.0K | ||
| Q3 24 | $3.4M | $-302.0K | ||
| Q2 24 | $-973.5K | $591.0K | ||
| Q1 24 | $2.8M | $-804.0K |
| Q4 25 | $334.7K | $-551.0K | ||
| Q3 25 | $1.5M | $-1.1M | ||
| Q2 25 | $363.6K | $-2.0M | ||
| Q1 25 | $-4.0M | $-749.0K | ||
| Q4 24 | $8.2M | $199.0K | ||
| Q3 24 | $3.2M | $-364.0K | ||
| Q2 24 | $-1.2M | $246.0K | ||
| Q1 24 | $2.4M | $-1.5M |
| Q4 25 | 2.2% | -5.9% | ||
| Q3 25 | 10.9% | -15.6% | ||
| Q2 25 | 2.7% | -26.1% | ||
| Q1 25 | -30.8% | -11.0% | ||
| Q4 24 | 55.9% | 2.1% | ||
| Q3 24 | 10.6% | -4.1% | ||
| Q2 24 | -4.1% | 2.9% | ||
| Q1 24 | 8.1% | -22.6% |
| Q4 25 | 9.9% | 3.4% | ||
| Q3 25 | 2.4% | 14.7% | ||
| Q2 25 | 3.8% | 0.8% | ||
| Q1 25 | 2.5% | 2.9% | ||
| Q4 24 | 8.1% | 5.3% | ||
| Q3 24 | 0.8% | 0.7% | ||
| Q2 24 | 0.9% | 4.1% | ||
| Q1 24 | 1.3% | 10.7% |
| Q4 25 | 1.86× | -4.12× | ||
| Q3 25 | 2.07× | — | ||
| Q2 25 | 9.30× | — | ||
| Q1 25 | -3.82× | — | ||
| Q4 24 | 532.98× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.97× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
